doctors in training

Houston medical school presents inaugural class as construction begins on new building

The University of Houston broke ground on its new medical school building and named the College of Medicine's inaugural class. Photo via UH.edu

This month, the University of Houston has taken a couple huge steps toward establishing a prestigious medical school program — the first new medical school to be established in Houston in almost 50 years.

UH has broken ground on its $80 million medical school building that is expected to be completed in 2022, and the program has named its inaugural class.

The new cohort of future doctors is a group diverse in ethnic background and life experience. The school plans to tackle a key issue in public health: the shortage of primary care doctors. These future doctors are charged by the university with eliminating health disparities in underserved urban and rural areas, which often have poorer health outcomes.

The UH College of Medicine received 1,728 applications for its first class of students; 164 applicants were interviewed for the 30 available spots, according to UH. An 18-member admissions committee screened those most likely to pursue primary care.

Here is a breakdown of UH's inaugural medical school class:

  • 30 students
  • 73 percent underrepresented minorities in medicine
  • 63 percent female
  • 57 percent first generation in college
  • 40 percent low socioeconomic status
  • 100 percent Texas resident
  • Five graduates of the University of Texas at Austin; two graduates each from the University of Houston, Baylor, Texas A&M, Houston Baptist, Prairie View A&M, and Rice University

According to the school, the goal is for 50 percent of graduates of the UH College of Medicine to choose primary care specialties including family medicine, general internal medicine, and general pediatrics. For some perspective, nationally, only about 20 percent of medical students choose primary care.

"We were very deliberate in our pursuit of medical students who fit the mission. This is much different than most other medical schools because we need different solutions for the current health care problems facing our city and state," said Dr. Stephen Spann, founding dean of the College of Medicine, in a statement.

Each student will receive a $100,000 four-year scholarship through philanthropy to cover tuition and fees. At full enrollment, the College of Medicine will have 480 students, per the school. The Health 2 Building in the UH Medical District will be the college's temporary home for the first two years until a new $80 million medical school building is completed in 2022. Construction crews broke ground on the new building on June 15, according to the university.

Being part of UH's inaugural medical school is deeply personal for students such as Cenk Cengiz. At 14, Cengiz's family emigrated from Turkey to Houston, but could not afford health insurance. Cengiz attended high school and college without ever seeing a doctor, which attracted him to the field of medicine and peaked his interest in the medical school's unique mission to help underserved communities.

"I came a long way from washing dishes at age 14 at a pizza store," Cengiz said in a statement. "My parents are super proud of me."

Dr. Stephen Spann is the founding dean of the College of Medicine. Photo via uh.edu

------

This article originally ran on CultureMap.

Trending News

Building Houston

 
 

From biomolecular research to oral cancer immunotherapy, here are three research projects to watch out for in Houston. Photo via Getty Images

Research, perhaps now more than ever, is crucial to expanding and growing innovation in Houston — and it's happening across the city right under our noses.

In InnovationMap's latest roundup of research news, a couple local scientists are honored by awards while another duo of specialists tackle a new project.

University of Houston professor recognized with award

Mehmet Orman of UH has been selected to receive an award for his research on persister cells. Photo via UH.edu

Mehmet Orman, assistant professor of chemical and biomolecular engineering at the University of Houston Cullen College of Engineering has been honored with a Faculty Early Career Development Award from the National Science Foundation. The award comes with a $500,000 grant to study persister cells — cells that go dormant and then become tolerant to extraordinary levels of antibiotics.

"Nearly all bacterial cultures contain a small population of persister cells," says Orman in a news release. "Persisters are thought to be responsible for recurring chronic infections such as those of the urinary tract and for creating drug-resistant mutants."

Previously, Orman developed the first methods to directly measure the metabolism of persister cells. He also developed cell sorting strategies to segregate persisters from highly heterogeneous bacterial cell populations, and, according to the release, he will be using his methods in the NSF research project.

Houston researchers collaborate on oral cancer innovation

Dr. Simon Young of UTHealth and Jeffrey Hartgerink of Rice University are working on a new use for an innovative gel they developed. Photo via Rice.edu

Two Houston researchers — chemist and bioengineer Jeffrey Hartgerink at Rice University and Dr. Simon Young at the University of Texas Health Science Center at Houston — have again teamed up to advance their previous development of a sophisticated hydrogel called STINGel. This time, they are using it to destroy oral cancer tumors.

SynerGel combines a pair of antitumor agents into a gel that can be injected directly into tumors. Once there, the gel controls the release of its cargo to not only trigger cells' immune response but also to remove other suppressive immune cells from the tumor's microenvironment. The duo reported on the technology in the American Chemical Society journal ACS Biomaterials Science & Engineering.

SynerGel, combines a pair of antitumor agents into a gel that can be injected directly into tumors, where they not only control the release of the drugs but also remove suppressive immune cells from the tumor's microenvironment.

"We are really excited about this new material," Hartgerink says in a news release. "SynerGel is formulated from a specially synthesized peptide which itself acts as an enzyme inhibitor, but it also assembles into a nanofibrous gel that can entrap and release other drugs in a controlled fashion.

In 2018, the pair published research on the use of a multidomain peptide gel — the original STINGel — to deliver ADU-S100, an immunotherapy drug from a class of "stimulator of interferon gene (STING) agonists."

The research is supported by the Oral and Maxillofacial Surgery Foundation, the National Institutes of Health, the Welch Foundation, the National Science Foundation and the Mexican National Council for Science and Technology.

Texas Heart Institute researcher honored by national organization

Dr. James Martin of Texas Heart Institute has been named a senior member of the National Academy of Inventors. Photo courtesy of THI

The National Academy of Inventors have named Houston-based Texas Heart Institute's Dr. James Martin, director of the Cardiomyocyte Renewal Lab, a senior member.

Martin is an internationally recognized developmental and regenerative biologist and his research is focused on understanding how signaling pathways are related to development and tissue regeneration.

"Dr. Martin has long been a steward of scientific advancement and has proven to be a tremendous asset to the Texas Heart Institute and to its Cardiomyocyte Renewal Lab through his efforts to translate fundamental biological discoveries in cardiac development and disease into novel treatment strategies for cardiac regeneration," says Dr. Darren Woodside, vice president for research at THI, in a news release. "Everyone at the Texas Heart Institute is thrilled for Dr. Martin, whose induction into the NAI as a Senior Member is well-deserved."

Martin has authored over 170 peer-reviewed papers in top journals he holds nine U.S. patents and applications, including one provisional application, all of which have been licensed to Yap Therapeutics, a company he co-founded.

The full list of incoming NAI Senior Members, which includes three professionals from the University of Houston, is available on the NAI website.

Trending News